Skip to main content
. Author manuscript; available in PMC: 2020 Dec 24.
Published in final edited form as: Leukemia. 2020 Jun 24;34(12):3269–3285. doi: 10.1038/s41375-020-0908-8

Figure 7. In vivo therapeutic potential of CARM1 inhibition against human DLBCL with lesions in CREBBP/EP300.

Figure 7.

A) Tumor volume of established Toledo Xenografts injected into the flanks of NOD-SCID mice, monitored over a 9-day treatment protocol with Vehicle (0.5% methylcellulose) or EZM2302 (CARM1iEZM) 150 mg/Kg twice a day. Error bars indicate SEM, n=16. B) Representative picture of Vehicle vs CARM1iEZM-treated tumor morphology from Toledo Xenografts. Bar in bottom right corner represents 1cm. C) Body weight of NOD-SCID Toledo recipients during 9-day treatment with Vehicle or CARM1iEZM. Error bars indicate SEM, n=16. D) Tumor volume of established U2932 Xenografts injected into the flanks of NOD-SCID mice, monitored over a 9-day treatment protocol with Vehicle (0.5% methylcellulose) or CARM1iEZM as above. Error bars indicate SEM, n=12. E) Representative picture of Vehicle vs CARM1iEZM-treated tumor morphology from U2932 Xenografts. Bar in bottom right corner represents 1cm. F) Body weight of NOD-SCID U2932 recipients during 9-day treatment with Vehicle or CARM1iEZM. Error bars indicate SEM, n=12.